In this line, a pan-FGFR inhibitor has been shown to impede cardiac hypertrophy (Faul et al., 2011; Di Marco et al., 2014) and dysfunction (Navarro-García et al., 2019) induced by FGF-23. Here, FGF23 is linked to cardiac hypertrophy.